Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06556173 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Study of VTX3232 in Parkinson's Disease
A Phase 2 study, sponsored by Zomagen Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT06556173: Completed Phase 2 study, sponsored by Zomagen Biosciences.
NCT06556173 is a Phase 2 study that has completed, run by Zomagen Biosciences. The registered enrollment target is 11 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06556173, a Phase 2 study, has completed, sponsored by Zomagen Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a study to understand if taking VTX3232 is safe in participants diagnosed with early stage idiopathic Parkinson's Disease (PD). Approximately 10 patients will take VTX3232 Dose A. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 7-day Pre-Baseline Period, a 28-day Open Label Treatment period (a participant receives active Dose A), and a 14-day Follow-Up Period.
Primary Outcome
Incidence of AEs and SAEs
Interventions
- DRUG VTX3232
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2025-04-04 |
| Phase | Phase 2 |
What the finished NCT06556173 record still lists
NCT06556173 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which VTX3232 is the first listed.
NCT06556173 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06556173 about?
NCT06556173 is a clinical study titled "Phase 2a Study of VTX3232 in Parkinson's Disease". This is a study to understand if taking VTX3232 is safe in participants diagnosed with early stage idiopathic Parkinson's Disease (PD). Approximately 10 patients will take VTX3232 Dose A. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 7-day Pre-...
What is the current status of trial NCT06556173?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2024-08-08. Estimated completion is 2025-04-04.
What interventions are being tested in trial NCT06556173?
The interventions under investigation include: VTX3232 (DRUG).
Who is sponsoring clinical trial NCT06556173?
This trial is sponsored by Zomagen Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06556173's enrollment target sits among peer trials
11 1967th of 2000 higher than 33 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI